One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...
4don MSN
Elliott Investment Management confirms a more than $2.5B stake in Phillips 66 and will seek to streamline the company, most ...
Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report. Vertex reported solid fourth-quarter numbers throughout its business. While the company's ...
Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a significant beat.
Getty revised its 2025 AFFO per share guidance to $2.38-$2.41, reflecting adjustments for the Zips Car Wash bankruptcy and related asset assumptions. Management expects to recapture a significant ...
has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance in 2024. The company revealed ...
Pharmaceuticals giant GlaxoSmithKline (GSK.L) (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback